
A balanced THC–CBD formulation was associated with substantial pain relief and improved daily function in two women with treatment-resistant trigeminal neuropathic pain—persistent facial pain involving the trigeminal nerve. Over eight weeks, pain scores fell from 9 to 4 in one patient and from 10 to 2 in the other.
Both patients had obtained insufficient relief from previous medications and local treatments. During cannabinoid treatment, chewing and oral hygiene improved, alongside quality-of-life measures. Sensory testing and three-dimensional facial imaging documented smaller sensitized areas, including resolution of allodynia—pain triggered by normally nonpainful stimulation—by week eight.
THC and CBD are cannabinoids found in Cannabis sativa. These case reports support further investigation of their combined use as an add-on approach for difficult-to-treat facial neuropathic pain. No serious adverse events were recorded, and controlled studies are needed to establish how reliably these benefits extend to other patients.
“Background: Trigeminal neuropathic pain (TNP) is a chronic and debilitating condition frequently resistant to conventional pharmacological therapies. Although cannabinoids have emerged as a potential adjunctive treatment, objective clinical documentation of their effects in orofacial neuropathic pain remains limited.
Case reports: We report two female patients with refractory TNP-one post-traumatic and one idiopathic-who experienced insufficient relief despite trials of anticonvulsants, antidepressants, topical agents, and local interventions. Both patients received a balanced tetrahydrocannabinol (THC):cannabidiol (CBD) sublingual formulation (20 mg/mL each) following a structured titration protocol and were monitored over 8 weeks. Outcomes were assessed using the Douleur Neuropathique 4 Questions (DN4), the visual analog scale (VAS), the World Health Organization Quality of Life-BREF (WHOQOL-Bref), and qualitative sensory testing (QualST). Additionally, three-dimensional facial stereophotogrammetry was employed to objectively quantify areas of hyperfunction and allodynia. Treatment resulted in a marked analgesic response (VAS reduction from 9 to 4 and from 10 to 2), qualitative changes in pain phenotype-from shock-like to predominantly burning-and functional improvement in mastication and oral hygiene. Stereophotogrammetry demonstrated a substantial reduction in sensitized regions, with extraoral hyperfunctional area decreasing from 113.72 to 27.54 cm2 and complete resolution of allodynia by week 8. WHOQOL-Bref scores improved in both patients, with physical domain scores increasing from 50.0 to 60.7 and from 25.0 to 39.3, accompanied by gains in psychological well-being. No serious adverse events were recorded.
Conclusion: These cases illustrate the potential clinical relevance of cannabinoids as an adjunctive approach for refractory TNP and highlight the importance of multidimensional assessment strategies. The findings should be interpreted cautiously given the descriptive nature of case reports; however, they underscore the need for controlled studies to further investigate the efficacy and safety of cannabinoid-based therapies in orofacial neuropathic pain.”
https://pubmed.ncbi.nlm.nih.gov/42088153
“This report describes two cases of refractory TNP in which adjunctive cannabinoid therapy was associated with improvements in pain characteristics, functional outcomes, and perceived quality of life, without serious adverse effects during the observation period. Given the inherent limitations of case reports, including the small sample and absence of a control condition, these findings should be interpreted with caution. Nevertheless, the cases highlight the potential clinical relevance of cannabinoids and support the need for well-designed controlled studies to further investigate their safety, efficacy, and therapeutic role in the management of TNP.”
